Clinical Trials for Non-Small Cell Lung Cancer

A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves adult patients with advanced or metastatic solid tumors with KRAS G12D mutation, assessing the safety and tolerability of the investigational drug INCB161734, a KRAS G12D inhibitor, both as a monotherapy and in combination with retifanlimab and cetuximab. Participants must have disease progression on standard treatments or be intolerant, ineligible, or have no other options, with specific cohorts for PDAC, CRC, NSCLC, and other tumors.

ClinicalTrials.gov ID: NCT06179160

A Phase 1/2 Study of BMS-986449 Alone and in Combination With Nivolumab in Participants With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: The trial investigates the safety and efficacy of BMS-986449, an orally administered investigational drug, both as a monotherapy and in combination with the anti-PD-1 antibody nivolumab, in patients with advanced, unresectable, or metastatic solid tumors, with specific cohorts for non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC).

ClinicalTrials.gov ID: NCT05888831

A First-in-Human (FiH) Study of IK-595, an Oral Dual MEK/RAF Inhibitor, in Patients With RAS-or RAF-altered Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial evaluates IK-595, an investigational oral dual MEK/RAF inhibitor, in patients aged 18 and over with advanced solid tumors characterized by RAS or RAF alterations, for whom no remaining standard treatments are available.

ClinicalTrials.gov ID: NCT06270082

A Phase 1/2 Study of PRO1107 in Patients With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves patients with advanced solid tumors, such as ovarian, endometrial, triple negative breast, non-small cell lung, and gastroesophageal cancers, who have previously received systemic therapies, and assesses the safety and efficacy of PRO1107, a PTK7-targeted antibody-drug conjugate with cytotoxic activity.

ClinicalTrials.gov ID: NCT06171789

A Phase I, Open-label, Multi-center Study of KFA115 as a Single Agent and in Combination With Pembrolizumab in Patients With Select Advanced Cancers

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: The trial involves patients with various advanced cancers, such as non-small cell lung cancer and triple negative breast cancer, testing the safety and tolerability of KFA115, an investigational immunomodulatory small molecule, alone and with pembrolizumab, a PD-(L)1 inhibitor.

ClinicalTrials.gov ID: NCT05544929

A Phase Ib/II, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Glumetinib (SCC244), a Selective MET Inhibitor in Patients With Advanced Non-Small Cell Lung Cancer Harboring MET-alterations

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial assesses the efficacy and safety of Glumetinib, a selective MET kinase inhibitor, in patients with advanced non-small cell lung cancer harboring MET alterations, including those with METex14 skipping mutations or MET amplification, who may have been previously treated with MET inhibitors.

ClinicalTrials.gov ID: NCT04270591

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule, in Subjects with Unresectable, Locally Advanced, or Metastatic Solid Tumors That Are Antigen-rich (START-001)

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial investigates the safety and efficacy of STAR0602, a bifunctional antibody-fusion molecule targeting T cell receptors to boost anti-tumor immunity, in patients with unresectable, locally advanced, or metastatic antigen-rich solid tumors such as metastatic triple negative breast cancer and castration-resistant prostate cancer. The treatment is especially for those with high tumor mutation burdens or resistance to PD-1 inhibitors.

ClinicalTrials.gov ID: NCT05592626

A Phase 1/2a, Multicenter, First-in-human, Open-label Clinical Trial Evaluating MDX2001 Monotherapy in Patients With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves adult patients with advanced solid tumors, evaluating the safety, tolerability, and efficacy of MDX2001, a tetraspecific antibody targeting CD3, CD28, TROP2, and c-MET, aiming to enhance T cell activity and overcome tumor heterogeneity.

ClinicalTrials.gov ID: NCT06239194

A Phase I/II Study of Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab in Advanced Solid Tumors (PNeoVCA)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial involves adults with unresectable or metastatic advanced solid tumors who have progressed on prior treatments or are candidates for pembrolizumab, combining pembrolizumab, which targets the PD-1 receptor to enhance immune response, with a personalized neoantigen peptide vaccine designed to stimulate an individualized immune attack against tumor-associated proteins.

ClinicalTrials.gov ID: NCT05269381

A Phase 1a/1b, Open-Label, Multi-Center, Dose Escalation and Expansion Study of HFB200603 (Anti-BTLA Antibody) as a Single Agent and in Combination With Tislelizumab (Anti-PD-1 Antibody) in Adult Patients With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves adult patients with advanced solid tumors, such as renal cell carcinoma, non-small cell lung cancer, and melanoma, who have received multiple prior therapies, and evaluates the safety and tolerability of HFB200603, an anti-BTLA antibody, both alone and in combination with tislelizumab, an anti-PD-1 antibody.

ClinicalTrials.gov ID: NCT05789069